In addition to positron emission tomography (PET) imaging, t-tau and p-tau CSF biomarkers are currently being utilized to support the clinical diagnosis of patients on the AD continuum and to identify individuals in the preclinical stages of the disease [8,9,10]. This evidence concerns the gene MAPT and Alzheimer disease.